Given that the inhibition of both B7-H3 and LPAR1 could impede CAFs' proliferation and subsequently reduce NSCLC cell proliferation and tumor growth, it would be prudent to explore LPAR1/B7-H3 inhibitory strategies in NSCLC treatment regimens [72]. Here, CD276 is linked to neoplasm.